With a desperate need for more research into treatments for Covid-19, Juicy Fields examines the ways in which CBD could help.
The world has been battling the Covid-19 crisis since 2020. The number of global infections and deaths keeps rising. As of 16 January 2022, the international infection numbers stood at 326,813,089, while the deaths reached 5,553,745.
According to research studies, CBD shows potential as a possible antiviral agent. The research is still in its early stages, and some studies have only been conducted in vitro. There is a growing need for the research to be advanced further, especially considering the virus’s rate of mutating.
CBD may prevent infection and stabilise the aggressive immune response
According to a study published in March 2021, CBD may be essential during the early stages of the SARS-CoV-2 infection. The researchers treated cells with CBD 24 hours before infecting them with SARS-CoV-2. CBD effectively suppressed the viral infection and promoted the destruction of the viral RNA. CBD, directly and indirectly, induces interferon production, enabling the body to fight the virus.
The researchers additionally analysed 93,000 patients tested for Covid-19. The results indicated that individuals that were taking FDA-approved CBD before the test showed a reduced risk of contracting SARS-CoV-2.
The study further supported previous studies relating to CBD and its function in inhibiting cytokine activation. SARS-CoV-2 attacks and weakens a host’s respiratory system. As a response, the immune system has an overactive inflammatory response. This leads to a cytokine storm, the leading cause of Acute Respiratory Distress Syndrome, characterised by fluids in the alveoli. Consequently, severe tissue damage leads to multiple organ failure and death.
In summary, this study concludes that CBD acts as an antiviral agent in the early stages of SARS-CoV-2 infection. Additionally, the cannabinoid helps stabilise the aggressive immune response during the advanced stages of infection.
CBD and CBG acidic precursors may prevent SARS-CoV-2 from penetrating human cells
Another notable study was conducted recently by researchers from Oregon State University. According to the results, CBDA and CBGA, which are acidic precursors of CBD and CBG, respectively, show potential in blocking SARS-CoV-2 and emerging variants from entering human cells. Cell penetration is one of the virus’s main processes before infecting the host.
The research team used a proprietary screening technique to identify the two acidic cannabinoids. The team concluded that Cannabigerol acid and Cannabidiol acid, at specific potency levels, helped minimise the infections by half. This is a promising result that needs to be explored further. The authors of the study noted that for this to work in humans, the potency of the CBDA and CBGA needs to be considerably high, but it is not impossible to achieve.
The different variants and the consequent spread of the virus have raised concerns worldwide. The most prevalent mutations are Alpha and Beta, which CBGA and CBDA block effectively. The scientists are hopeful that the results will be replicated in other studies involving different variants, such as Omicron, Delta, Gamma, and others.
Supporting pre-covid study on CBD and Asthma
A pre-covid study conducted in 2019 looked into the effectiveness of cannabidiol (CBD) in reducing the inflammation of the lungs and managing airways hyper-responsiveness. Although the study was not on SARS-CoV-2, it does prove how CBD works to inhibit cytokine production. The study concluded that different dosages of CBD help to stabilise airway hyper-responsiveness. However, only high doses of cannabidiol seemed to combat lung inflammation.
The research on the effects of CBD on SARS-CoV-2 is still in its infancy stage. There is a growing need for more studies as the cannabinoid promises a lasting, diverse solution. With new variants popping from different parts of the world, having a solution that cuts across the mutations will bring about much-needed relief.
Other ways CBD can help with Covid-19
One of the symptoms of Covid-19 is pain, which can stem from body aches or headaches. Numerous studies have concluded that CBD does possess potent analgesic properties. The cannabinoid is widely used as a pain-reliever by hundreds of individuals, especially since its legal status is no longer complicated. General perspective and attitudes towards CBD are positive, especially for people who have confirmed its efficiency. Covid patients can utilise CBD to combat pain.
Since the pandemic struck, the number of individuals experiencing anxiety has significantly increased. Patients with Covid face great fear of being incapacitated and possibly dying. The growing mortality rate fuels this fear. CBD is a natural anxiolytic that can aid in alleviating anxiety.
According to Your Covid Recovery, many Covid patients experience changes in their sleep cycle. While some find it challenging to fall asleep, others experience interrupted sleep, keeping them awake most of the night. CBD helps restore the normal sleep cycle, leaving patients refreshed and healthier.
CBD presents as a potential antiviral agent in the treatment of SARS-CoV-2. Research suggests that CBD can help prevent infection and stabilise aggressive immune responses to the virus. More research is needed to solidify these findings. CBD is readily available, comes in various forms, has minimal side effects, and is self-administered. This makes the ideal treatment option if or when it is confirmed in large-scale studies. You too can help the researchers by joining the world’s leading cannabis crowdgrowing platform, as part of their funds are destined to investigation programs that can help understand the numerous benefits of this ancient plant.
New grant funds for “life changing” medical cannabis prescriptions in Jersey
Jersey residents can now apply for a grant from the Sapphire Medical Foundation
Jersey residents can now apply for a grant to fund a medical cannabis prescription, from the UK’s only medical cannabis charity, Sapphire Medical Foundation.
Thanks to new funding, patients on the island of Jersey can now apply for a grant to fully support a medical cannabis prescription.
Those selected who meet the eligibility criteria, will have their prescriptions and clinic appointments be paid for by the Sapphire Medical Foundation for a minimum of one year.
Medical cannabis was legalised for prescription in 2018 across the UK, since then the growth in patient numbers paying privately for treatment has risen exponentially.
Eligible patients can seek treatment for conditions including chronic pain, neuropathic pain, generalised anxiety disorder and fibromyalgia.
In Jersey, there are now an estimated 3,000 patients prescribed the treatment via private clinics, such as Sapphire Medical Clinics.
The cost associated with prescriptions for medical cannabis can be a barrier to what is for some people a life-changing medication.
As a result, some patients are faced with the decision between prioritising their health or other necessities – never more so than in the current economic squeeze with living costs rising.
Sapphire Medical Foundation’s mission is to reduce the economic barriers of access to medical cannabis. It was founded to relieve financial difficulties that can affect individuals who are unable to afford the costs associated with medical cannabis prescriptions.
No other charity in the UK exists with the sole purpose of alleviating the monetary burden that comes with cannabis-based treatment. Thus, the Sapphire Medical Foundation presents the only legitimate option for medical cannabis access for hundreds, if not thousands of individuals.
Kirran Gill was the first patient in the UK to receive support from the Sapphire Medical Foundation for rheumatoid arthritis, fibromyalgia and anxiety and says that because of treatment, her pain levels have been significantly easier to manage and the severe side effects from using conventional treatment (such as opioids) are less severe.
Additionally, her appetite, nausea, anxiety, and overall mood have improved. Access to medical cannabis has greatly impacted her life in a positive way.
Dr Simon Erridge, co-founder and trustee of Sapphire Medical Foundation commented: “We want to help as many patients as possible in the Island community and thank those who have made this new funding round possible.
“We are delighted to invite residents who meet our stringent grant making criteria to apply for support to access medical cannabis for a minimum of one year.”
This grant round opens to Jersey applicants on the 17 May 2022, closing 6th June 2022. Applications are open to both existing medical cannabis prescription holders, and patients who otherwise meet the grant-making criteria but have not accessed treatment to date.
Applications can be made on Sapphire’s website. All grants are made following a thorough assessment of eligibility and in accordance with fair and transparent grant making principles to available here.
The Sapphire Medical Foundation provides financial assistance to cover the costs of treatment for a minimum of one year for each patient who receives one of the grants.
Sapphire Medical Foundation will launch an additional grant round in summer 2022 which shall be open to all UK patients and those in the Channel Islands.
Research to shed light on how UK clinicians view medical cannabis
UK medical professionals are invited to take part in a new outreach project
A new research project aims to get to the bottom of why many UK clinicians are still reluctant to prescribe medical cannabis.
Medical cannabis patient and psychology student, Hallie Heeg, is inviting UK medical professionals to participate in a new outreach project, which aims to shed light on their views and knowledge around prescribing medical cannabis.
Heeg, who is originally from the US, has more than a decade of experience working in the field of addiction and eating disorder recovery – which enlightened her to the role cannabis can play in holistic healing.
After entering recovery from an eating disorder herself in 2006, Heeg began managing rehab clinics and went onto work for the Hazelden Betty Ford Foundation, the largest non-profit addiction and mental health programme in the States.
“In the addiction field it’s drugs or no drugs, it’s very black and white, but I started seeing people who were sober, using psychedelics for trauma work in a clinical way – but they were having to keep it hidden,” she says.
“I got really frustrated by that, because if as clinicians, their creed was to do no harm and to put the patient first, we should be looking at all these different types of modalities and different medications and not just putting our beliefs into one.”
Heeg self-medicated for many years before accessing a cannabis prescription, finding that it helped ease her anxiety and quieten the negative thoughts of her eating disorder.
“I’ve used it throughout the years, but more from a recreational perspective,” she explains.
“[When I got my prescription] I started seeing my anxiety decrease, I started seeing the negative thoughts going away and I was having a healthier relationship with food. Slowly I was able to reduce the prescription drugs I was on.”
The question of why
Moving to the UK after meeting her husband, Heeg got a coaching certificate and founded her own coaching and intervention service, WeRise, to continue supporting patients through recovery. Last year, she went on to enrol on a Masters programme in psychology at the University of East London.
For her dissertation she has collaborated with the UK’s drug reform charity, Drug Science, to try to understand the attitudes of clinicians towards medical cannabis.
“There are something like 1.4 million medical cannabis users in the UK, however, that’s typically those who have to source it from the illegal market,” she says.
“I really want to understand why people aren’t prescribing and why the numbers on the illicit market are so big in the UK, but yet the amount of medical cannabis users being able to access it legally is so small.”
The first step in the project is a five minute, anonymous survey for doctors and prescribing nurses across the country.
“There are not a lot of studies around medical cannabis in terms of doctor’s knowledge, particularly in the UK, because it is so new,” says Heeg.
“Myself and Drug Science are hoping to raise awareness around this and from a patient advocate standpoint, but equally from a medical and research standpoint, help inform them on how they could actually become prescribers.”
She adds: “It will also help us with making decisions and determining policies, by really understanding what the views of the medical community are, why they believe this and how we can debunk any myths around it.”
Medical cannabis and eating disorders
After completing her Masters, Heeg plans to open her own eating disorder clinic and treatment centre.
Having seen the benefits of medical cannabis both personally and through her clients, she would like to see more research and discussion around its use in these conditions.
“I really have seen great results with it, typically in anorexics and bulimics, and my hope is that we can play a part in doing more research around that,” she says.
“Every week we hear about how eating disorder services are in crisis, there’s a shortage of beds, the number of adolescents struggling is rising – it’s the number one mortality among any mental illness. And yet we don’t seem to put a lot of effort into research around that when it comes to medical cannabis.”
However, her colleagues in the field – and that of addiction – have been reluctant to engage so far.
“When I sent my survey out to those contacts, I got several responses back saying ‘I work in addiction, why would I take the survey?’ And since I sent it out to my eating disorder network, I haven’t gotten a response back,” says Heeg.
“It feels a little vulnerable for me to kind of put this research out there, because there’s a community that I’ve been a part of that also looks at it as this gateway drug.”
She adds: “It’s been challenging, to be honest with you, to find clinicians who are even interested in taking a survey with the word medical cannabis in.”
Doctors and prescribing nurses in the UK can complete the anonymous survey here
Fibromyalgia diaries: Travelling as a medical cannabis patient
Medical cannabis patient, Julia Davenport, on the challenges of travelling with a prescription.
While cannabis oil has dramatically improved fibromyalgia patient Julia Davenport’s quality of life, it has brought with it new challenges when it comes to travel, as she explains here.
Chronic pain has a nasty habit of getting in the way of doing the things you love.
My big passion which I share with my husband, and I guess our one extravagance, is jetting off to far flung places.
Over the years, however, fibromyalgia, arthritis and aching joints have conspired to make travelling evermore arduous.
Now in my 70s with various replacement parts, difficult terrain is one of the biggest barriers to exploring new places.
Certainly, my husband’s bucket list destination, the Galapagos Islands, is on my no-fly list. I would have adored to go there at some point, but navigating those volcanic rocks, even with my walking stick, would be a nightmare.
Familiar holiday spots closer to home are also becoming increasingly inaccessible. Every year our extended family visits the same Northumberland cottage, which is at the bottom of a steep bank.
In years gone by, I’d be fine to walk down to it through the working farm in which it stands. Now, because my back and shoulders have deteriorated, I have to drive right to the door.
Finding ways to compensate for the things you can no longer do is a constant theme with chronic pain conditions.
Aside from mobility challenges, another restriction on travel with rheumatological conditions can be the weather, and humidity can play havoc with chronic pain. I’d love to go to Central America, for example, but I just couldn’t tolerate the heat and humidity.
Having said that, although hot dry weather is far better than the cold British winter, the difference is not enough to drag me away from my family at Christmas time.
For all my gripes about life on the road, though, traveling remains my great joy, and discovering medical cannabis and CBD has definitely helped; although it’s not all plain sailing.
Travelling with medical cannabis
In November I’m returning to South Africa, a place I’ve visited a few times and which has a special place in my heart.
On previous visits, because we’ve flown via Dubai, I’ve not taken medical cannabis or CBD with me.
There is no way I’d risk taking cannabis with me to the UAE, where people have apparently been arrested and put in jail for having codeine, never mind anything else, despite having a prescription for it.
They have a ridiculously long list of substances that they deem addictive which you can’t have. There are things you can apply for permission to take, but I just wouldn’t trust that I wasn’t going to get arrested.
When we’ve flown long-haul through Dubai in the past, I would tend to take enough medication just for the journey. I have even flushed pain medication down the toilet on a connecting flight to Dubai just to make sure I’m not in possession on arrival.
I’ve then managed to pick up cannabis products quite easily in certain final destinations.
In South Africa there was a shop similar to a Holland and Barrett which sold CBD products legally. They were able to match the equivalent of what I was already taking to their products.
In Japan, it was also relatively easy to buy CBD over the counter, even with the language barrier.
In the past, the ease at which you can buy CBD has definitely influenced my travel choices. There are lots of countries that I’d give a wide berth to because of their approach to medication, which is often underpinned by false views on addiction.
At the same time, with so many countries opening up to CBD, travelling is getting easier and the main challenge is the routing of flights through the Gulf.
Thankfully on my next trip to South Africa we are travelling direct to Cape Town directly so I can rest easy that I won’t end up behind bars.
Guidance for travelling with medical cannabis
Some countries allow medicinal cannabis and some even recreational cannabis. Some allow CBD but others do not.
Guidance from the Medical Cannabis Clinicians Society recommends that patients always contact the embassy to check the legal situation in the country they are visiting before travelling with medical cannabis.
Some countries require a letter of proof from a clinician, some require a request to be submitted to the embassy requesting to travel, some restrict the amount of medication you are able to travel with, i.e. up to 30 days supply. It is suggested that any guidance is sought and confirmed in writing.
It is advised that travellers keep medication on their person, stored in its original packaging along with a copy of their issued prescription and relevant corresponding paperwork.
You can get an idea of the country’s stance on cannabis initially by searching for “legality of cannabis” on Wikipedia – but always check with the embassy as well.
- How THC and CBD work together in the brain – new study
- Four of the best CBD transdermal products
- Grow Pharma launches new low-priced flower range for UK patients
- New grant funds for “life changing” medical cannabis prescriptions in Jersey
- Research to shed light on how UK clinicians view medical cannabis
- Why patients in Europe are accessing medical cannabis
- News2 years ago
Community extends support to cannabis icon Rick Simpson
- News2 years ago
Cancer survivor claims cannabis oil helped her beat brain tumour
- Case Studies2 years ago
CBD oil and fibromyalgia – a case study
- News2 years ago
NHS lines up cannabis medicine manufacturing
- News2 years ago
Living with chronic fatigue – my CBD story
- News1 year ago
UK grants second licence to grow high-THC medical cannabis
- Insight2 years ago
I’ve gone from a wheelchair to walking thanks to cannabis
- Feature2 years ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt